Top

Published in:

01-07-2013 | Review

Immune-suppressive properties of the tumor microenvironment

Authors: Jürgen C. Becker, Mads Hald Andersen, David Schrama, Per thor Straten

Published in: Cancer Immunology, Immunotherapy | Issue 7/2013

Abstract

Solid tumors are more than an accumulation of cancer cells. Indeed, cancerous cells create a permissive microenvironment by exploiting non-transformed host cells. Thus, solid tumors rather resemble abnormal organs composed of the cancerous cells itself and the stroma providing the supportive framework. The stroma can be divided into the extracellular matrix consisting of proteoglycans, hyaluronic acid, and fibrous proteins, as well as stromal cells including mesenchymal and immune cells; moreover, it contains various peptide factors and metabolites. Here, we will focus on immune-modulating capacities of the tumor microenvironment.

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. doi:10.1016/j.cell.2011.02.013 PubMedCrossRef

Pietras K, Östman A (2010) Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res 316:1324–1331. doi:10.1016/j.yexcr.2010.02.045 PubMedCrossRef

Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867. doi:10.1038/nature01322 PubMedCrossRef

de Visser KE, Korets LV, Coussens LM (2005) De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7:411–423. doi:10.1016/j.ccr.2005.04.014 PubMedCrossRef

Colotta F, Allavena P, Sica A et al (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30:1073–1081. doi:10.1093/carcin/bgp127 PubMedCrossRef

Egeblad M, Nakasone ES, Werb Z (2010) Tumors as organs: complex tissues that interface with the entire organism. Dev Cell 18:884–901. doi:10.1016/j.devcel.2010.05.012 PubMedCrossRef

Rosenberg SA (2012) Raising the bar: the curative potential of human cancer immunotherapy. Sci Transl Med 4:127ps8. doi:10.1126/scitranslmed.3003634 PubMedCrossRef

Kerkar SP, Restifo NP (2012) Cellular constituents of immune escape within the tumor microenvironment. Cancer Res 72:3125–3130. doi:10.1158/0008-5472.CAN-11-4094 PubMedCrossRef

Bronte V, Mocellin S (2009) Suppressive influences in the immune response to cancer. J Immunother 32:1–11. doi:10.1097/CJI.0b013e3181837276 PubMedCrossRef

10.

Andersen MH, Schrama D, thor Straten P, Becker JC (2006) PS_JID_5700001.indd. J Invest Dermatol 126:32–41. doi:10.1038/sj.jid.5700001 PubMedCrossRef

11.

Hajishengallis G, Chavakis T (2013) Endogenous modulators of inflammatory cell recruitment. Trends Immunol 34:1–6. doi:10.1016/j.it.2012.08.003 PubMedCrossRef

12.

Brennan PJ, Brigl M, Brenner MB (2013) Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat Rev Immunol 13:101–117. doi:10.1038/nri3369 PubMedCrossRef

13.

Mantovani A (2009) The yin-yang of tumor-associated neutrophils. Cancer Cell 16:173–174. doi:10.1016/j.ccr.2009.08.014 PubMedCrossRef

14.

Matzinger P, Kamala T (2011) Tissue-based class control: the other side of tolerance. Nat Rev Immunol 11:221–230. doi:10.1038/nri2940 PubMedCrossRef

15.

Hofmann UB, Houben R, Bröcker E-B, Becker JC (2005) Role of matrix metalloproteinases in melanoma cell invasion. Biochimie 87:307–314. doi:10.1016/j.biochi.2005.01.013 PubMedCrossRef

16.

Yu Q, Stamenkovic I (2000) Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Gen Dev 14:163–176

17.

Sheu BC, Hsu SM, Ho HN et al (2001) A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res 61:237–242PubMed

18.

Boutet P, Agüera-González S, Atkinson S et al (2009) Cutting edge: the metalloproteinase ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein. J Immunol 182:49–53PubMed

19.

Scheller J, Chalaris A, Garbers C, Rose-John S (2011) ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol 32:380–387. doi:10.1016/j.it.2011.05.005 PubMedCrossRef

20.

Godefroy E, Manches O, Dréno B et al (2011) Matrix metalloproteinase-2 conditions human dendritic cells to prime inflammatory TH2 cells via an IL-12- and OX40L-dependent pathway. Cancer Cell 19:333–346. doi:10.1016/j.ccr.2011.01.037 PubMedCrossRef

21.

Godin-Ethier J, Hanafi LA, Piccirillo CA, Lapointe R (2011) Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin Cancer Res 17:6985–6991. doi:10.1158/1078-0432.CCR-11-1331 PubMedCrossRef

22.

Platten M, Wick W, Van den Eynde BJ (2012) Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res 72:5435–5440. doi:10.1158/0008-5472.CAN-12-0569 PubMedCrossRef

23.

Zou W, Restifo NP (2010) TH17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 10:248–256. doi:10.1038/nri2742 PubMedCrossRef

24.

Weinlich G, Murr C, Richardsen L et al (2007) Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients. Dermatology 214:8–14. doi:10.1159/000096906 PubMedCrossRef

25.

Smith C, Chang MY, Parker KH et al (2012) IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov 2:722–735. doi:10.1158/2159-8290.CD-12-0014 PubMedCrossRef

26.

Andersen MH (2012) The specific targeting of immune regulation: T-cell responses against indoleamine 2,3-dioxygenase. Cancer Immunol Immunother 61:1289–1297. doi:10.1007/s00262-012-1234-4 PubMedCrossRef

27.

Pilotte L, Larrieu P, Stroobant V et al (2012) Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc Nat Acad Sci 109:2497–2502. doi:10.1073/pnas.1113873109 PubMedCrossRef

28.

Nowak EC, de Vries VC, Wasiuk A et al (2012) Tryptophan hydroxylase-1 regulates immune tolerance and inflammation. J Exp Med 209:2127–2135. doi:10.1084/jem.20120408 PubMedCrossRef

29.

Bronte V, Zanovello P (2005) Regulation of immune responses by l-arginine metabolism. Nat Rev Immunol 5:641–654. doi:10.1038/nri1668 PubMedCrossRef

30.

Rundhaug JE, Simper MS, Surh I, Fischer SM (2011) The role of the EP receptors for prostaglandin E2 in skin and skin cancer. Cancer Metastasis Rev 30:465–480. doi:10.1007/s10555-011-9317-9 PubMedCrossRef

31.

Chouaib S, Messai Y, Couve S et al (2012) Hypoxia promotes tumor growth in linking angiogenesis to immune escape. Front Immunol 3:21. doi:10.3389/fimmu.2012.00021 PubMedCrossRef

32.

Wink DA, Hines HB, Cheng RYS et al (2011) Nitric oxide and redox mechanisms in the immune response. J Leuk Biol 89:873–891. doi:10.1189/jlb.1010550 CrossRef

33.

Jayaraman P, Parikh F, Lopez-Rivera E et al (2012) Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release. J Immunol 188:5365–5376. doi:10.4049/jimmunol.1103553 PubMedCrossRef

34.

Singer K, Gottfried E, Kreutz M, Mackensen A (2011) Suppression of T-cell responses by tumor metabolites. Cancer Immunol Immunother 60:425–431. doi:10.1007/s00262-010-0967-1 PubMedCrossRef

35.

Hirschhaeuser F, Sattler UGA, Mueller-Klieser W (2011) Lactate: a metabolic key player in cancer. Cancer Res 71:6921–6925. doi:10.1158/0008-5472.CAN-11-1457 PubMedCrossRef

36.

Shime H, Yabu M, Akazawa T et al (2008) Tumor-secreted lactic acid promotes IL-23/IL-17 proinflammatory pathway. J Immunol 180:7175–7183PubMed

37.

Cham CM, Gajewski TF (2005) Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cells. J Immunol 174:4670–4677PubMed

38.

Mandapathil M, Szczepanski MJ, Szajnik M et al (2010) Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J Biol Chem 285:27571–27580. doi:10.1074/jbc.M110.127100 PubMedCrossRef

39.

Stagg J, Smyth MJ (2010) Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 29:5346–5358. doi:10.1038/onc.2010.292 PubMedCrossRef

40.

Haskó G, Linden J, Cronstein B, Pacher P (2008) Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 7:759–770. doi:10.1038/nrd2638 PubMedCrossRef

41.

Waickman AT, Alme A, Senaldi L et al (2012) Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor. Cancer Immunol Immunother 61:917–926. doi:10.1007/s00262-011-1155-7 PubMedCrossRef

42.

Su Y, Jackson EK, Gorelik E (2011) Receptor desensitization and blockade of the suppressive effects of prostaglandin E(2) and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes. Cancer Immunol Immunother 60:111–122. doi:10.1007/s00262-010-0924-z PubMedCrossRef

43.

Häusler SFM, Montalbán del Barrio I, Strohschein J et al (2011) Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity. Cancer Immunol Immunother 60:1405–1418. doi:10.1007/s00262-011-1040-4 PubMedCrossRef

44.

Kryczek I, Wu K, Zhao E et al (2011) IL-17+ regulatory T Cells in the microenvironments of chronic inflammation and cancer. J Immunol 186:4388–4395. doi:10.4049/jimmunol.1003251 PubMedCrossRef

45.

Ryzhov S, Novitskiy SV, Goldstein AE et al (2011) Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+ Gr1+ Cells. J Immunol 187:6120–6129. doi:10.4049/jimmunol.1101225 PubMedCrossRef

46.

Beavis PA, Stagg J, Darcy PK, Smyth MJ (2012) CD73: a potent suppressor of antitumor immune responses. Trends Immunol 33:231–237. doi:10.1016/j.it.2012.02.009 PubMedCrossRef

47.

Jin D, Fan J, Wang L et al (2010) CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res 70:2245–2255. doi:10.1158/0008-5472.CAN-09-3109 PubMedCrossRef

48.

Garber K (2011) Beyond ipilimumab: new approaches target the immunological synapse. J Nat Cancer Inst 103:1079–1082. doi:10.1093/jnci/djr281 PubMedCrossRef

49.

Cameron F, Whiteside G, Perry C (2011) Ipilimumab: first global approval. Drugs 71:1093–1104. doi:10.2165/11594010-000000000-00000 PubMedCrossRef

50.

Callahan MK, Wolchok JD, Allison JP (2010) Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol 37:473–484. doi:10.1053/j.seminoncol.2010.09.001 PubMedCrossRef

51.

Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517–2526. doi:10.1056/NEJMoa1104621 PubMedCrossRef

52.

Reck M, Bondarenko I, Luft A et al (2013) Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 24:75–83. doi:10.1093/annonc/mds213 PubMedCrossRef

53.

Di Giacomo AM, Ascierto PA, Pilla L et al (2012) Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol 13:879–886. doi:10.1016/S1470-2045(12)70324-8 PubMedCrossRef

54.

Postow MA, Callahan MK, Barker CA et al (2012) Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366:925–931. doi:10.1056/NEJMoa1112824 PubMedCrossRef

55.

Santegoets SJAM, Stam AGM, Lougheed SM et al (2012) T cell profiling reveals high CD4(+)CTLA-4 (+) T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment. Cancer Immunol Immunother. doi:10.1007/s00262-012-1330-5 PubMed

56.

Hodis R, Watson IR, Kryukov GV et al (2012) A landscape of driver mutations in melanoma. Cell 150:251–263. doi:10.1016/j.cell.2012.06.024 PubMedCrossRef

57.

Downey SG, Klapper JA, Smith FO et al (2007) Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 13:6681–6688. doi:10.1158/1078-0432.CCR-07-0187 PubMedCrossRef

58.

Liakou CI, Kamat A, Tang DN et al (2008) CTLA-4 blockade increases IFNgamma-producing CD4+ ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Nat Acad Sci 105:14987–14992. doi:10.1073/pnas.0806075105 PubMedCrossRef

59.

Ji R-R, Chasalow SD, Wang L et al (2012) An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 61:1019–1031. doi:10.1007/s00262-011-1172-6 PubMedCrossRef

60.

Hamid O, Schmidt H, Nissan A et al (2011) A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 9:204. doi:10.1186/1479-5876-9-204 PubMedCrossRef

61.

Shahabi V, Whitney G, Hamid O et al (2012) Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab. Cancer Immunol Immunother 61:733–737. doi:10.1007/s00262-012-1227-3 PubMedCrossRef

62.

la Fuente de H, Cibrián D, Sánchez-Madrid F (2012) Immunoregulatory molecules are master regulators of inflammation during the immune response. FEBS Lett 586:2897–2905. doi:10.1016/j.febslet.2012.07.032 CrossRef

63.

Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454. doi:10.1056/NEJMoa1200690 PubMedCrossRef

64.

Brahmer JR, Tykodi SS, Chow LQM et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455–2465. doi:10.1056/NEJMoa1200694 PubMedCrossRef

65.

Hobo W, Novobrantseva TI, Fredrix H et al (2012) Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation. Cancer Immunol Immunother. doi:10.1007/s00262-012-1334-1 PubMed

66.

Seliger B, Quandt D (2012) The expression, function, and clinical relevance of B7 family members in cancer. Cancer Immunol Immunother 61:1327–1341. doi:10.1007/s00262-012-1293-6 PubMedCrossRef

67.

Yi KH, Chen L (2009) Fine tuning the immune response through B7-H3 and B7-H4. Immunol Rev 229:145–151. doi:10.1111/j.1600-065X.2009.00768.x PubMedCrossRef

68.

Textor S, Fiegler N, Arnold A et al (2011) Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. Cancer Res 71:5998–6009. doi:10.1158/0008-5472.CAN-10-3211 PubMedCrossRef

69.

Vetter CS, Groh V, thor Straten P et al (2002) Expression of stress-induced MHC class I related chain molecules on human melanoma. J Invest Dermatol 118:600–605. doi:10.1046/j.1523-1747.2002.01700.x PubMedCrossRef

70.

Champsaur M, Lanier LL (2010) Effect of NKG2D ligand expression on host immune responses. Immunol Rev 235:267–285. doi:10.1111/j.0105-2896.2010.00893.x PubMed

71.

Waldhauer I, Goehlsdorf D, Gieseke F et al (2008) Tumor-associated MICA is shed by ADAM proteases. Cancer Res 68:6368–6376. doi:10.1158/0008-5472.CAN-07-6768 PubMedCrossRef

72.

Siemens DR, Hu N, Sheikhi AK et al (2008) Hypoxia increases tumor cell shedding of MHC class I chain-related molecule: role of nitric oxide. Cancer Res 68:4746–4753. doi:10.1158/0008-5472.CAN-08-0054 PubMedCrossRef

73.

Barsoum IB, Hamilton TK, Li X et al (2011) Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide. Cancer Res 71:7433–7441. doi:10.1158/0008-5472.CAN-11-2104 PubMedCrossRef

74.

Pruessmeyer J, Ludwig A (2009) The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer. Semin Cell Dev Biol 20:164–174. doi:10.1016/j.semcdb.2008.09.005 PubMedCrossRef

75.

Paschen A, Sucker A, Hill B et al (2009) Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res 15:5208–5215. doi:10.1158/1078-0432.CCR-09-0886 PubMedCrossRef

76.

Benitez AC, Dai Z, Mann HH et al (2011) Expression, signaling proficiency, and stimulatory function of the NKG2D lymphocyte receptor in human cancer cells. Proc Nat Acad Sci 108:4081–4086. doi:10.1073/pnas.1018603108 PubMedCrossRef

77.

Rak J (2013) Extracellular vesicles—biomarkers and effectors of the cellular interactome in cancer. Front Pharmacol 4:21. doi:10.3389/fphar.2013.00021 PubMedCrossRef

78.

Taylor DD, Doellgast GJ (1979) Quantitation of peroxidase-antibody binding to membrane fragments using column chromatography. Anal Biochem 98:53–59PubMedCrossRef

79.

Taylor DD, Gercel-Taylor C (2011) Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments. Semin Immunopathol 33:441–454. doi:10.1007/s00281-010-0234-8 PubMedCrossRef

80.

Filipazzi P, Bürdek M, Villa A et al (2012) Recent advances on the role of tumor exosomes in immunosuppression and disease progression. Sem Cancer Biol 22:342–349. doi:10.1016/j.semcancer.2012.02.005 CrossRef

81.

Huber V, Filipazzi P, Iero M et al (2008) More insights into the immunosuppressive potential of tumor exosomes. J Transl Med 6:63. doi:10.1186/1479-5876-6-63 PubMedCrossRef

82.

van der Heyde HC, Gramaglia I, Combes V et al (2011) Flow cytometric analysis of microparticles. Methods Mol Biol 699:337–354. doi:10.1007/978-1-61737-950-5_16 PubMedCrossRef

83.

Whiteside TL (2013) Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). Biochem Soc Trans 41:245–251. doi:10.1042/BST20120265 PubMedCrossRef

84.

Xiang X, Poliakov A, Liu C et al (2009) Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer 124:2621–2633. doi:10.1002/ijc.24249 PubMedCrossRef

Title: Immune-suppressive properties of the tumor microenvironment
Authors: Jürgen C. Becker
Mads Hald Andersen
David Schrama
Per thor Straten
Publication date: 01-07-2013
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 7/2013
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-013-1434-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2013

Therapy model for advanced intracerebral B16 mouse melanoma using radiation therapy combined with immunotherapy

Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects

Anti-metastatic potential of human Vδ1+ γδ T cells in an orthotopic mouse xenograft model of colon carcinoma

EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumors

Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study)

Efficient ex vivo induction of T cells with potent anti-tumor activity by protein antigen encapsulated in nanoparticles

Keynote webinar | Spotlight on antibody–drug conjugates in cancer